A phase II Study of Bortezomib (Velcade), a proteasome Inhibitor, in treating patients with idiopathic Myelofibrosis (IM) randomized to receive new investigational drugs.
Phase of Trial: Phase II
Latest Information Update: 31 May 2011
At a glance
- Drugs Bortezomib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- 31 May 2011 New trial record